Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PTCT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Sepiapterin FDA approved Jul 2025 · Sephience |
Phenylketonuria | Phase 3 · NCT06302348 | Recruiting |
| Deflazacort FDA approved Feb 2017 · Emflaza |
Limb-Girdle Muscular Dystrophy | Phase 3 · NCT03783923 | Terminated |
| Levodopa | CTNNB1 | N/A · NCT07614126 | Recruiting |
| Ataluren | Duchenne Muscular Dystrophy | Phase 3 · NCT01247207 | Terminated |
| Vatiquinone | Friedreich Ataxia | Phase 3 · NCT05515536 | Active not recruiting |
| Unesbulin (PTC596) | Leiomyosarcoma | Phase 2/3 · NCT05269355 | Terminated |
| Emvododstat (PTC299) | Pneumonia | Phase 2/3 · NCT04439071 | Terminated |
| EPI-589 | Amyotrophic Lateral Sclerosis | Phase 2 · NCT02460679 | Completed |
| EPI-743 | Leigh Syndrome | Phase 2 · NCT01721733 | Completed |
| Gene Therapy Agent | Aromatic L-amino Acid Decarboxylase (AADC) Deficiency | Phase 1/2 · NCT01395641 | Completed |
| PTC844 | Rheumatoid Arthritis | Phase 2 · NCT07779616 | Recruiting |
| PTC857 | Amyotrophic Lateral Sclerosis | Phase 2 · NCT05349721 | Terminated |
| Chronic Corticosteroid Therapy | Duchenne Muscular Dystrophy | Phase 2 · NCT01009294 | Terminated |
| AAV2-hAADC | Aromatic Amino Acid Decarboxylase Deficiency | Phase 2 · NCT02926066 | Completed |
Also used in these trials (approved or third-party drugs, not PTCT's own candidates): Dacarbazine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PTCT holds $2.1B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PTCT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 11,904,696 | 14.25% | 2025-11-30 |
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 7,193,433 | 8.61% | 2026-03-31 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 5,512,555 | 6.60% | 2026-09-30 |
| Wellington Management Group LLP | Institution (13G, 5%+) | 5,287,260 | 6.33% | 2026-09-30 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 4,871,329 | 5.83% | 2026-03-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 4,284,448 | 5.13% | 2026-03-31 |
| Michael Schmertzler Director |
Insider | 1,454,860 | 1.74% | 2026-10-14 |
| Matthew B. Klein CHIEF EXECUTIVE OFFICER, Director |
Insider | 383,868 | 0.46% | 2026-08-04 |
| Mark Elliott Boulding EXEC. VP AND CLO · +47,268 options |
Insider | 105,272 | 0.13% | 2026-10-09 |
| Pierre Gravier CHIEF FINANCIAL OFFICER |
Insider | 83,986 | 0.10% | 2026-07-14 |
| Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
Insider | 79,115 | 0.09% | 2026-04-02 |
| Eric Pauwels CHIEF BUSINESS OFFICER |
Insider | 73,411 | 0.09% | 2026-06-10 |
Share count 83,544,284 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-07-29 | — | NDA | -10.5% | +11.2% | +17.8% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PTCT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →